SAM v. DOJ: The Lawsuit That Could Undo Cannabis Rescheduling, Explained

Federal cannabis rescheduling moved fast in 2026 — and so did the legal challenges to it. In April 2026, the Department of Justice officially moved state-regulated medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. By May 4, the anti-legalization group Smart Approaches to Marijuana (SAM) had filed a petition for review in the U.S. Court of Appeals for the D.C. Circuit. The case — SAM v. DOJ, consolidated as Case #26-1106 — could unwind everything the rescheduling order accomplished if the challengers prevail. Here is what you need to know.

Who Filed the Lawsuit and Why

SAM filed its initial petition on May 4, 2026. The D.C. Circuit subsequently consolidated SAM's challenge with similar petitions from the Attorneys General of Nebraska and Indiana, and from the pharmaceutical company MMJ International Holdings. Louisiana initially joined but later withdrew.

These challengers are not a unified bloc — SAM is a policy advocacy organization that opposes legalization, while the state AGs represent state governments with various drug enforcement interests, and MMJ is a pharmaceutical company with commercial interests in the cannabis market. What they share is opposition to how the rescheduling was executed.

The Core Legal Arguments

The petitioners raise three main arguments, each targeting a different dimension of how DOJ executed the rescheduling.

1. Procedural Violations Under the Administrative Procedure Act

The Administrative Procedure Act (APA) requires federal agencies to give the public notice and an opportunity to comment before making major regulatory changes. The challengers argue DOJ bypassed that process by moving state-licensed medical cannabis to Schedule III immediately, without a public comment period. The DOJ's position is that the rescheduling fell under a treaty-compliance provision of the Controlled Substances Act (Section 811(d)(1)) that does not require the standard notice-and-comment process. The D.C. Circuit will need to decide which reading of the statute is correct.

2. Exceeding Statutory Authority

SAM and its co-petitioners argue that Acting Attorney General Todd Blanche exceeded his authority under the Controlled Substances Act. The specific target is DOJ's use of Section 811(d)(1) — a provision originally designed for treaty compliance — as the legal basis to skip ordinary rulemaking. The challengers contend this provision does not grant the authority the DOJ claims it does.

3. International Treaty Conflict

The 1961 Single Convention on Narcotic Drugs, to which the United States is a signatory, requires member nations to maintain strict controls on cannabis. The challengers argue that placing cannabis in Schedule III violates this treaty obligation. This is a complex argument because treaty interpretation is itself a contested legal area — but the D.C. Circuit takes international law arguments seriously, and this line of attack cannot be dismissed outright.

Where the Case Stands as of August 2026

The immediate flashpoint in the case is the petitioners' motion to stay the rescheduling order while the litigation plays out. A stay would effectively freeze the Schedule III status and revert cannabis to Schedule I treatment while the courts work through the merits.

The DOJ opposed the stay motion in July 2026, arguing the petitioners lack legal standing because they have not suffered a concrete injury. The DOJ's argument is that losing drug-testing revenue (as NDASA, one of the co-petitioners, alleges) and policy disagreement (as SAM argues) do not constitute the kind of specific, cognizable harm federal courts require to grant standing. If the D.C. Circuit agrees that none of the challengers have standing, the case ends without reaching the merits.

The Parallel DEA Hearing

Running alongside the D.C. Circuit case is a separate DEA administrative hearing process covering broader rescheduling — including recreational cannabis, not just the state-licensed medical market addressed by the April 2026 order. That DEA hearing concluded on July 15, 2026. An Administrative Law Judge set an August 17, 2026 deadline for post-hearing briefs from all parties. The DEA's administrative process and the D.C. Circuit case are legally distinct but politically connected — the outcome of one could influence the trajectory of the other.

What Happens If the Challengers Win

If the D.C. Circuit vacates the rescheduling order on APA grounds, cannabis reverts to Schedule I. That would unwind a series of practical changes that followed the April 2026 order: the VA's updated internal guidance allowing doctors to discuss cannabis with patients, certain banking improvements, and the signal effect of Schedule III status on state-level enforcement priorities.

It would not directly affect state cannabis markets in DC, Maryland, or Virginia, which operate under their own state law frameworks. But it would represent a significant setback for the federal reform trajectory and could complicate ongoing discussions about banking access, interstate commerce, and federal employment.

What Happens If DOJ Prevails

If the court finds the challengers lack standing, or upholds the rescheduling order on the merits, Schedule III status remains in place for state-licensed medical cannabis. The DEA's separate broader rescheduling process continues on its own timeline. The legal landscape would stabilize — at least until the broader rescheduling rulemaking works through the courts.

What It Means for DMV Consumers Right Now

In practical terms, nothing changes for DC, Maryland, or Virginia cannabis consumers in the immediate term because of this lawsuit. State cannabis markets operate under state authority. The rescheduling order did not open new retail locations, change purchasing limits, or alter how delivery services operate at the state level.

The Bud Lords Cannabis Newsroom will continue tracking this case as the D.C. Circuit rules on the stay motion and, eventually, the merits. For a broader look at the federal rescheduling process and what the August 17 DEA brief deadline means, see our coverage of the federal cannabis rescheduling hearings.

In the meantime, licensed cannabis delivery in DC remains available. Browse our full menu for lab-tested flower, concentrates, and edibles delivered to your door.

The Bottom Line

SAM v. DOJ is the most consequential cannabis legal challenge pending in the federal courts right now. The standing question will likely determine whether the case reaches a ruling on the merits. If the D.C. Circuit finds standing and rules against the rescheduling, federal cannabis reform faces a significant setback. If the court dismisses for lack of standing or upholds the order, Schedule III status is confirmed and the broader rescheduling process moves forward on the DEA's timeline. The next major milestone is the August 17 post-hearing brief deadline in the DEA administrative proceeding — watch that date.

While the litigation plays out, the DC cannabis market continues to operate. Browse Bud Lords' full selection of flower, pre-rolls, concentrates, and edibles at shop all products — licensed delivery across DC.

This article was researched and written with AI assistance by the Bud Lords AI Newsroom.